Brief Report: Urine Tenofovir Levels Strongly Correlate with Virologic Suppression in Patients with HIV on Tenofovir Alafenamide-Based Antiretroviral Therapy.
Kelly A JohnsonHideaki OkochiMireya ArreguinJoseph WatabeDavid V GliddenAnindita ChattopadhyayElizabeth ImbertMatthew D HickeyMonica GandhiMatthew SpinelliPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
We found that urine tenofovir (TFV) levels >1500 ng/ml strongly predict virologic suppression among patients with HIV taking tenofovir alafenamide (TAF, OR 5.66; 95% CI 1.59-20.14; p = 0.007). This suggests an existing point-of-care assay developed for tenofovir disoproxil fumarate (TDF) will support adherence monitoring for patients on all TFV-based antiretrovirals.